Logo image of ACRV

ACRIVON THERAPEUTICS INC (ACRV) Stock Fundamental Analysis

NASDAQ:ACRV - Nasdaq - US0048901096 - Common Stock - Currency: USD

5.54  +0.03 (+0.54%)

After market: 5.54 0 (0%)

Fundamental Rating

3

Taking everything into account, ACRV scores 3 out of 10 in our fundamental rating. ACRV was compared to 572 industry peers in the Biotechnology industry. While ACRV has a great health rating, there are worries on its profitability. ACRV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ACRV had negative earnings in the past year.
In the past year ACRV has reported a negative cash flow from operations.
ACRV Yearly Net Income VS EBIT VS OCF VS FCFACRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

ACRV has a Return On Assets of -35.86%. This is in the better half of the industry: ACRV outperforms 60.56% of its industry peers.
With a decent Return On Equity value of -39.10%, ACRV is doing good in the industry, outperforming 71.55% of the companies in the same industry.
Industry RankSector Rank
ROA -35.86%
ROE -39.1%
ROIC N/A
ROA(3y)-25.37%
ROA(5y)N/A
ROE(3y)-28.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ACRV Yearly ROA, ROE, ROICACRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -100 -200 -300 -400

1.3 Margins

ACRV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRV Yearly Profit, Operating, Gross MarginsACRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ACRV has been increased compared to 1 year ago.
ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACRV Yearly Shares OutstandingACRV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 5M 10M 15M 20M
ACRV Yearly Total Debt VS Total AssetsACRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 4.34 indicates that ACRV is not in any danger for bankruptcy at the moment.
ACRV's Altman-Z score of 4.34 is fine compared to the rest of the industry. ACRV outperforms 79.06% of its industry peers.
ACRV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.34
ROIC/WACCN/A
WACCN/A
ACRV Yearly LT Debt VS Equity VS FCFACRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 12.75 indicates that ACRV has no problem at all paying its short term obligations.
ACRV has a Current ratio of 12.75. This is amongst the best in the industry. ACRV outperforms 85.69% of its industry peers.
ACRV has a Quick Ratio of 12.75. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ACRV (12.75) is better than 85.69% of its industry peers.
Industry RankSector Rank
Current Ratio 12.75
Quick Ratio 12.75
ACRV Yearly Current Assets VS Current LiabilitesACRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

ACRV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.12%.
EPS 1Y (TTM)-1.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.61%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ACRV will show a decrease in Earnings Per Share. The EPS will decrease by -1.58% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6.22%
EPS Next 2Y-2.12%
EPS Next 3Y-1.83%
EPS Next 5Y-1.58%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACRV Yearly Revenue VS EstimatesACRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
ACRV Yearly EPS VS EstimatesACRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRV. In the last year negative earnings were reported.
Also next year ACRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRV Price Earnings VS Forward Price EarningsACRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRV Per share dataACRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.12%
EPS Next 3Y-1.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACRV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (3/7/2025, 8:03:27 PM)

After market: 5.54 0 (0%)

5.54

+0.03 (+0.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-26 2025-03-26/amc
Inst Owners57.6%
Inst Owner Change0.37%
Ins Owners9.71%
Ins Owner Change-1.98%
Market Cap172.52M
Analysts82.35
Price Target21.53 (288.63%)
Short Float %5.99%
Short Ratio19.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.6%
Min EPS beat(2)-0.13%
Max EPS beat(2)15.33%
EPS beat(4)2
Avg EPS beat(4)3.62%
Min EPS beat(4)-15.99%
Max EPS beat(4)15.33%
EPS beat(8)6
Avg EPS beat(8)7.7%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.06%
PT rev (3m)-2.06%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.4%
EPS NY rev (3m)0.4%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.88
P/tB 0.88
EV/EBITDA N/A
EPS(TTM)-2.7
EYN/A
EPS(NY)-2.85
Fwd EYN/A
FCF(TTM)-2.05
FCFYN/A
OCF(TTM)-1.95
OCFYN/A
SpS0
BVpS6.32
TBVpS6.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.86%
ROE -39.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-25.37%
ROA(5y)N/A
ROE(3y)-28.19%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 363.84%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.75
Quick Ratio 12.75
Altman-Z 4.34
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)481.03%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%10.61%
EPS Next Y6.22%
EPS Next 2Y-2.12%
EPS Next 3Y-1.83%
EPS Next 5Y-1.58%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-36.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.57%
OCF growth 3YN/A
OCF growth 5YN/A